IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer ...
Zacks Investment Research on MSN
UTHR stock rises 12.5% on promising data from TETON-1 Tyvaso study
Shares of United Therapeutics UTHR rallied 12.5% on Monday after the company unveiled robust data from the phase III TETON-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results